Clinical Pharmacology & Therapeutics10.1002/cpt.38520161003212-214The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapyLC Villaruz, MA Socinski,
Journal of Pathology and Translational Medicine10.4132/jptm.2020.02.172020542196-196Correction of acknowledgments: PD-L1 testing in non-small cell lung cancer: past, present, and futureHyojin Kim, Jin-Haeng Chung,,
Journal of Pathology and Translational Medicine10.4132/jptm.2019.04.242019534199-206PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and FutureHyojin Kim, Jin-Haeng Chung,,
Lung Cancer10.1016/s0169-5002(19)30086-82019127S18Are endobronchial ultrasound-guided transbronchial needle aspiration samples adequate for PD-L1 testing in non-small cell lung cancer?W. Falconer, N. Bhatt, A. Medford,
Lung Cancer10.1016/j.lungcan.2019.03.0112019132152-153What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?Sara Bravaccini,
Lung Cancer10.1016/j.lungcan.2003.08.009200342S35-S40Combined modality therapy for non-small cell lung cancer, past, present, and futureDong Wook Kim, Hak Choy,
Lung Cancer10.1016/s0169-5002(02)00356-220023837-43Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancerMartin J Edelman,
Clinical Lung Cancer10.1016/j.cllc.2020.02.0242020214308-313The Story of Angiogenesis Inhibitors in Non–small-cell Lung Cancer: The Past, Present, and FutureNikhil Atul Shukla, Melissa Noela Yan, Nasser Hanna,
Lung Cancer10.1016/j.lungcan.2016.06.01620169979-87Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancerKazuhiko Shien, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba,
Lung Cancer10.1016/0169-5002(95)90723-81995132230Concurrent chemoradiation for stage III non small cell lung cancer: Present results and future prospects,